EYAL MUSCAL to Interleukin 1 Receptor Antagonist Protein
This is a "connection" page, showing publications EYAL MUSCAL has written about Interleukin 1 Receptor Antagonist Protein.
Connection Strength
1.780
-
Systemic inflammatory markers and EEG features of children with FIRES receiving anakinra. Ann Clin Transl Neurol. 2023 03; 10(3):440-446.
Score: 0.766
-
Combined Systemic Immunotherapy and Intrathecal Dexamethasone in Febrile Infection Related Epilepsy Syndrome. Ann Clin Transl Neurol. 2025 Apr; 12(4):871-875.
Score: 0.221
-
Second-line immunotherapy in new onset refractory status epilepticus. Epilepsia. 2024 May; 65(5):1203-1223.
Score: 0.207
-
Variation in Early Anakinra Use and Short-Term Outcomes in Multisystem Inflammatory Syndrome in Children. Arthritis Rheumatol. 2023 08; 75(8):1466-1476.
Score: 0.196
-
Severe Pediatric COVID-19 Pneumonia Treated With Adjuvant Anakinra. Hosp Pediatr. 2022 05 01; 12(5):e162-e170.
Score: 0.182
-
Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Ann Clin Transl Neurol. 2020 12; 7(12):2467-2474.
Score: 0.165
-
Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): A Report from FIRES workshop. Epilepsia Open. 2021 03; 6(1):62-72.
Score: 0.042